<DOC>
	<DOCNO>NCT02954601</DOCNO>
	<brief_summary>This study enroll approximately 30 adult subject T2DM age 20 75 inclusive . Following 7-10 day Screening period , eligible subject enter 3-day single-blind placebo run-in . On Day 4 , subject randomize treatment sequence include three treatment assignment three treatment Periods accord randomization scheme .</brief_summary>
	<brief_title>A Study Single Multiple Doses ORMD-0801 ( Study Drug ) Placebo Subjects With T2 ( Type 2 ) DM ( Diabetes Mellitus )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male female subject , age 20 75 year , inclusive type 2 diabetes mellitus . At Visit 2/Period 1/Day 1 , subject treat diabetes metformin ( ≥1000 mg/day ; type regimen ) , metformin DPP4 inhibitor ( DipeptidylPeptidase ) 4 ) , metformin SGLT2 ( Sodiumglucose cotransporter 2 ) inhibitor , metformin TZD ( Thiazolidinediones ) , metformin sulfonylurea . Subjects stable regimen metformin ( define metformin dose type ) treatment least 8 week prior Visit 2/Period 1/Day 1 . Body Mass Index ( BMI ) 25 40 kg/m2 , inclusive , Screening . Hemoglobin A1c ( HbA1c ) ≥7.5 ≤10.5 % Screening . Fasting serum glucose great equal 126 mg/dL Screening . Females childbearing potential must negative serum pregnancy test result Screening negative urine pregnancy test Visit 2/Day 1 study Periods . Females childbearing potential define : i. Postmenopausal ( define least 12 month menses woman ≥45 year age ) ii . Has hysterectomy and/or bilateral oophorectomy , bilateral salpingectomy , bilateral tubal ligation/occlusion least 6 week prior screen ; OR iii . Has congenital acquire condition prevents childbearing . Females childbearing potential agree avoid become pregnant receiving study treatment 14 day last dose study treatment comply one following : i. practice abstinence† heterosexual activity OR ii . Use ( partner use ) acceptable contraception heterosexual activity . Usage antidiabetic agent metformin , sulfonylurea , SGLT2 inhibitor , TZD , DPP4 inhibitor within 6 week prior Visit 2/Period 1/Day 1 . Presence clinically significant endocrine disease accord Investigator ( euthyroid subject replacement therapy include dosage thyroxine stable least six week prior Screening ) . Clinical diagnosis type 1 diabetes . Fasting serum glucose &gt; 300 mg/dL Screening ; single repeat test allowable . Evidence unawareness hypoglycemia , document plasma glucose ≤50 mg/dL absence symptom hypoglycemia Screening . Presence clinically significant condition ( opinion Investigator ) might interfere evaluation study medication , significant renal , hepatic , gastrointestinal ( GI ) , cardiovascular ( CV ) , immune disease , blood dyscrasia disorder cause hemolysis unstable red blood cell , clinically important hematological disorder ( i.e . aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Screening . Presence history cancer within past 5 year Screening , exception adequatelytreated localized basal cell skin cancer situ uterine cervical cancer . 1 . A subject history malignancy &gt; 5 year prior Screening evidence residual recurrent disease . 2 . A subject history melanoma , leukemia , lymphoma , renal carcinoma exclude . Laboratory abnormality Screening include : 1 . Cpeptide &lt; 1.0 ng/mL ; 2 . Positive pregnancy test female childbearing potential ( Screening Visit 2/Periods 13/Day 1 ) ; 3 . Abnormal serum thyrotropin ( TSH ) level low limit normal &gt; 1.5X ( 1.5 time ) upper limit normal 4 . Elevated liver enzyme ( alanine transaminase ( ALT ) , alanine aminotransferase ( AST ) , alkaline phosphatase ) &gt; 2X upper limit normal . 5 . Very high triglyceride level ( &gt; 600 mg/dL ) ; single repeat test allowable . 6 . Any relevant abnormality would interfere efficacy safety assessment study treatment administration . Positive history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic hepatitis B C , primary biliary cirrhosis , active symptomatic gallbladder disease . Positive history HIV . Use follow medication : 1 . History use insulin 1 week within 6 month prior none within 6 week prior Visit 2/Period 1/Day 1 . 2 . History use aprotinin time prior Screening ( e.g. , Trasylol , type dose ) . 3 . Administration thyroid preparation thyroxine ( except subject stable replacement therapy ) within 6 week prior Screening . 4 . Administration systemic longacting corticosteroid within two month prolong use ( one week ) systemic corticosteroid inhale corticosteroid ( daily dosage &gt; 1,000 μg equivalent beclomethasone ) within 30 day prior Screening . Intraarticular and/or topical corticosteroid consider systemic . 5 . Use medication know modify glucose metabolism decrease ability recover hypoglycemia oral , parenteral , inhaled steroid ( discuss ) , immunosuppressive immunomodulating agent . Subject weight loss program maintenance phase , subject start weight loss medication ( e.g. , orlistat liraglutide ) , within 8 week prior Screening . Subjects bariatric surgery also exclude . Subject pregnant breastfeeding . Subject Screening systolic blood pressure ≥165 mmHg diastolic blood pressure ≥100 mmHg . Subjects allowed take BP rescue medication . Subject user recreational illicit drug recent history ( within 1 year Screening ) drug alcohol abuse dependence . ( Note : Alcohol abuse include heavy alcohol intake define &gt; 3 drink per day &gt; 14 drink per week , binge drinking ) Screening . Any clinically significant ECG abnormality Screening cardiovascular disease . Clinically significant cardiovascular disease include : 1 . History stroke , transient ischemic attack , myocardial infarction within 6 month prior Screening , 2 . History currently New York Heart Associate Class IIIV heart failure prior Screening , One contraindication metformin . At Principal Investigator 's discretion , condition factor deem unsuitable subject enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Oral Insulin</keyword>
	<keyword>DM T2 ( Diabetes Mellitus Type 2 )</keyword>
</DOC>